intismeran autogene
2 stories
-
healthNew mRNA Vaccine Combo Slashes Melanoma Recurrence Risk by 49%
Merck-Moderna personalized mRNA cancer vaccine plus KEYTRUDA reduces melanoma recurrence or death risk over five years.
-
healthmRNA Vaccine Slashes Melanoma Recurrence Risk in Landmark Trial
A new mRNA cancer therapy from Merck and Moderna cuts melanoma recurrence or death risk by 49% over five years, offering new hope for late-stage patients.